Complete Remission of Basal Cell Carcinoma Following Treatment With Cemiplimab After 2 Years

Dumann, Konstantin; Artz, Niklas; Ziemer, Mirjana

doi:10.1001/jamadermatol.2021.2206

Cited by 6 publications

(7 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CRs have been reported with cemiplimab in the setting of BCC (table 1). Five CRs were reported in the phase II trial leading to cemiplimab’s FDA approval for metastatic or advanced BCC, and two other cases were described in case reports 5 9 10. During the phase II trial, the overall time to response (partial and complete) was 4.3 months.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Complete response of a large basosquamous carcinoma following treatment with cemiplimab and vismodegib

et al. 2023

View full text Add to dashboard Cite

The anti-PD-1 antibody cemiplimab has demonstrated effectiveness in the setting of locally advanced basal cell carcinoma (BCC) and squamous cell carcinoma. We describe a case of a large, locally invasive basosquamous carcinoma, an aggressive type of BCC, invading the left sternocleidomastoid muscle with near compression of the left internal jugular vein producing a severe anaemia secondary to ulceration and chronic blood loss. The patient was initially started on vismodegib monotherapy but failed to respond. He was then started on cemiplimab in addition to vismodegib. Improvement was noted after one cycle. After 21 cycles of cemiplimab, the left shoulder ulcerated lesion was completely re-epithelialised. He remains in complete remission after 31 cycles of cemiplimab in addition to vismodegib.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The patient was in remission 8 months after stopping therapy 9. Dumman et al describe a CR of a 20 mm x 45 mm BCC of the nasolabial fold that demonstrated a CR after 12 months of cemiplimab therapy 10. The patient remained in CR 4 months after discontinuing therapy 10.…”

Section: Discussionmentioning

confidence: 99%

Complete response of a large basosquamous carcinoma following treatment with cemiplimab and vismodegib

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Although the reported trial showed the efficacy and safety of cemiplimab for the treatment of patients with advanced BCC, to date, only one case from real-life experience has already been described in the literature [ 51 ].…”

Section: New Emerging Therapies For Advanced Bccmentioning

confidence: 99%

New Emerging Treatment Options for Advanced Basal Cell Carcinoma and Squamous Cell Carcinoma

et al. 2022

View full text Add to dashboard Cite

Non-melanoma skin cancers, also known as keratinocyte tumors, have an increasing incidence worldwide, with basal cell carcinoma and squamous cell carcinoma being the most represented ones. Although surgery represents the gold-standard treatment for both tumors, some cases can progress to an advanced or a metastatic state and targeted therapy is required. Hedgehog signaling pathway has an important role in the development of basal cell carcinoma, and its inhibition is the key to new treatment options available for the treatment of locally advanced and metastatic basal cell carcinoma. Cutaneous squamous cell carcinoma is the second most frequent malignant skin cancer; when presenting in advanced or metastatic stage, alternative treatments are required; cemiplimab is a human monoclonal antibody directed against programmed cell death-1 receptor that acts by blocking T-cell inactivation and is the first drug approved for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma. Studies evaluating pembrolizumab, ipilimumab and nivolumab as alternative treatments for advanced squamous cell carcinoma are still underway. Objective of this review is to analyze and discuss the novel therapies for advanced basal cell carcinoma and squamous cell carcinoma to obtain a sharper perspective of the available treatment options.

show abstract

“…Data have been published for patients with la-BCC (84 subjects), highlighting an objective RR of 31% (95% CI: 21–42%), DCR of 79.8%, and median estimated progression-free survival (PFS of 19.3 months) for all patients; these results granted FDA approval as previously mentioned [ 12 ]. Moreover, cases of durable remission are increasingly being documented [ 48 , 49 ].…”

Section: The Role Of Immunotherapy In Non-melanoma Skin Cancermentioning

confidence: 99%

Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response

Zelin

Maronese

Dri

et al. 2022

JCM

View full text Add to dashboard Cite

Background: Non-melanoma skin cancer (NMSC) stands as an umbrella term for common cutaneous malignancies, including basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), together with rarer cutaneous cancers, such as Merkel cell carcinoma (MCC) and other forms of adnexal cancers. The majority of NMSCs can be successfully treated with surgery or radiotherapy, but advanced and metastatic stages may require systemic approaches such as immunotherapy with immune checkpoint inhibitors (ICIs). Summary: Since immunotherapy is not effective in all patients and can potentially lead to severe adverse effects, an important clinical question is how to properly identify those who could be suitable candidates for this therapeutic choice. In this paper, we review the potential features and biomarkers used to predict the outcome of ICIs therapy for NMSCs. Moreover, we analyze the role of immunotherapy in special populations, such as the elderly, immunocompromised patients, organ transplant recipients, and subjects suffering from autoimmune conditions. Key messages: Many clinical, serum, histopathological, and genetic features have been investigated as potential predictors of response in NMSCs treated with ICIs. Although this field of research is very promising, definitive, cost-effective, and reproducible biomarkers are still lacking and further efforts are needed to validate the suggested predictors in larger cohorts.

show abstract

Complete Remission of Basal Cell Carcinoma Following Treatment With Cemiplimab After 2 Years

Abstract: The effectiveness and safety of topical β-receptor blocker in treating superficial infantile haemangiomas: a meta-analysis including 20 studies.

Cited by 6 publications

References 11 publications

Complete response of a large basosquamous carcinoma following treatment with cemiplimab and vismodegib

Complete response of a large basosquamous carcinoma following treatment with cemiplimab and vismodegib

New Emerging Treatment Options for Advanced Basal Cell Carcinoma and Squamous Cell Carcinoma

Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response

Contact Info

Product

Resources

About